Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
GLYCONEO, GLNEO (KSJ Pharmatech)
Product name
GLYCONEO, GLNEO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
130 (255 working days)
Active ingredients
neostigmine methylsulfate, glycopyrronium bromide (glycopyrrolate)
Registration type
New generic medicine
Indication
Reversal of residual non-depolarising (competitive) neuromuscular block.
Registration process
First generic
First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine